:jbake-type: post
:jbake-status: published
:jbake-title: “Is curing patients a sustainable business model?” Goldman Sachs analysts ask | Ars Technica
:jbake-tags: économie,science,médecine,_mois_avr.,_année_2018
:jbake-date: 2018-04-13
:jbake-depth: ../
:jbake-uri: shaarli/1523595348000.adoc
:jbake-source: https://nicolas-delsaux.hd.free.fr/Shaarli?searchterm=https%3A%2F%2Farstechnica.com%2Ftech-policy%2F2018%2F04%2Fcuring-disease-not-a-sustainable-business-model-goldman-sachs-analysts-say%2F&searchtags=%C3%A9conomie+science+m%C3%A9decine+_mois_avr.+_ann%C3%A9e_2018
:jbake-style: shaarli

https://arstechnica.com/tech-policy/2018/04/curing-disease-not-a-sustainable-business-model-goldman-sachs-analysts-say/[“Is curing patients a sustainable business model?” Goldman Sachs analysts ask | Ars Technica]

Les analystes de Goldman-Sachs font de l'analyse économique de la thérapie génique ... Et ça me fait vomir.
